Compare Amphastar Pharmaceuticals Inc (AMPH) vs General Motors Company (GM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs General Motors Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while General Motors Company trades at $77.8 (market cap $70.19B). The key difference: General Motors Company is far larger — about 85× Amphastar Pharmaceuticals Inc's market cap, and General Motors Company pays a 0.92% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | GM | |
|---|---|---|
Market Cap | $826.08M | $70.19B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $86.38 |
52-Week Low | $16.87 | $48.89 |
Enterprise Value | $1.22B | $173.53B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
General Motors (GM) trades at $77.85, up 1.57% with a bearish technical signal despite three consecutive quarterly earnings beats. The company maintains strong cash flow generation ($26.9B operating cash flow in 2025) and trades at discounted valuations (P/S 0.4, P/B 1.12). Recent news highlights GM's strategic pivot into energy and battery technology partnerships as automotive sales face industry headwinds.
GM presents a value opportunity with analyst consensus price target of $100.27 (29% upside) but faces execution risks in EV transition and margin pressure. The stock's outlook depends on Q2 earnings delivering clean cash flow and sustained margin improvement amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
